HomeAI · summaries
Storia in 10 fonti
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired Allergan, and Bristol Myers Squibb swallowed Celgene. | Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patients, Angus Liu argues in an editorial.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
- ·
letemps.ch
La potentielle fusion avec Bristol-Myers Squibb fait plonger AstraZeneca - Le Temps
Un possible rapprochement entre Bristol-Myers Squibb et AstraZeneca serait en discussion. Une union qui serait l’une des plus importantes opérations de l’histoire de l’industrie…
